Estrogen receptor beta (ERβ), a member of the nuclear receptor superfamily, is frequently upregulated in ccRCC and has been implicated in promoting tumor progression and angiogenesis.[9, 10] Importantly, angiogenesis in ccRCC is orchestrated not only by transcriptional programs but also by diverse post‐transcriptional and post‐translational layers of regulation.[8, 11] Hence, determining whether ERβ regulates pro‐angiogenic factors via post‐transcriptional and post‐translational routes could identify novel targets for ccRCC therapy. Here, ESR2 is linked to nonpapillary renal cell carcinoma.